

## Perivision secures CHF 2.4M to re-imagine eye testing with AI and VR

Lausanne, Switzerland — September 12, 2025.

Every year, millions of people risk losing their eyesight due to glaucoma and other diseases that often go undetected for too long. Globally, vision loss is estimated to cost the economy more than [USD 400B annually](#), a burden expected to rise sharply as populations age. Today's standard eye testing methods are resource-intensive, time-consuming, and inaccessible to many patients. Addressing this urgent challenge, [PeriVision SA](#), a Swiss medtech and AI spin-off from the University of Bern, is re-imagining eye testing. Its eye testing platform, [VisionOne](#) combines commercial VR headsets with advanced AI algorithms to deliver faster, more reliable and patient-friendly visual field testing for [100 million glaucoma](#) patients globally.

Today, the company announced a CHF 2.4 million (USD 3 million) seed funding round to expand its platform with additional VR eye tests, including [new tests for retina diseases](#), as well as advanced [AI insights tools](#) and systems integrations to provide a holistic solution for eye clinics, optometry practices and biopharma customers.

The funding round was led by [ARYA VC](#) with participation from a diverse group of new and existing investors, including [DART Ventures](#), [Zühlke Ventures](#), [MEDKAP](#), [SICTIC](#), Is Bank's AI Factory, [Venturekick](#), InaTec, Juchum Foundation, [CADFEM](#) and [OOMNIUM](#). This strategic mix of investors, ranging from venture capital funds to family offices and business angel clubs, brings extensive expertise in technology, healthcare, and scaling startups.



Picture: PeriVision team at the recent strategy & team retreat in Lausanne.

Apart from this recent funding round, PeriVision has been recognized for its innovation and potential with numerous grants and prizes over the past three years. The company won the [EIT](#)

[Health Wild Card](#), received two [Innosuisse project grants](#) to develop its innovative technology, was recognized in the Switzerland [TOP100 Startups](#), formed part of the [Venture Leaders Medtech 2023](#) cohort and was accepted into the [Innosuisse Scale-up Coaching](#) and [Biopôle Vanguard Accelerator](#) programs. These grants and awards underscore the significant validation the company has received from industry and government bodies.

### **New board members to accelerate growth**

"We are incredibly proud to welcome such a distinguished group of experienced investors to PeriVision," said Patrick Kessel, CEO of PeriVision. "This funding not only provides the capital we need to achieve our ambitious roadmap, but also strengthens our board with invaluable expertise."

As part of the investment, Arijana Walcott, Managing Director of DART Ventures, will join the PeriVision board.

"We believe in investing in founders who are tackling big problems with disruptive solutions," said Arijana Walcott. "But PeriVision also stands out for its strong IP and commercial traction, evidenced by early partnerships and product demand. This gave us the confidence that this team is uniquely positioned to redefine the future of ophthalmology."

Additionally, Sanem Tatlidil Özal, General Partner at ARYA VC, will join the board as an observer: "We at Arya VC invest in companies with a powerful mission and a diverse high-calibre team to execute it. We are excited to support PeriVision, as they scale their platform to make a global impact."

The new funding comes after PeriVision successfully launched its first product with certifications in key markets such as the EU, US and UK. The company will expand this presence in 2025.

### **About PeriVision SA – visionary eye testing for the 21<sup>st</sup> century**

PeriVision is a Swiss medtech & AI company founded in 2022 as a spin-off from the University of Bern. The company develops AI and VR-powered solutions to redefine eye testing, with a primary focus on optimizing visual field and perimetry testing for glaucoma patients. Its flagship product, VisionOne, is a cloud-based platform that allows doctors to perform eye tests using commercial VR headsets. By leveraging AI, PeriVision aims to improve clinical productivity, assist in diagnostic decisions, and enhance access to eye testing.

For more information about PeriVision and VisionOne, please visit [www.perivision.com](http://www.perivision.com) or contact [info@perivision.com](mailto:info@perivision.com).